Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response
- PMID: 33649191
- DOI: 10.1158/1078-0432.CCR-20-4753
Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response
Comment on
-
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Clin Cancer Res. 2020 May 15;26(10):2354-2361. doi: 10.1158/1078-0432.CCR-19-3663. Epub 2020 Feb 26. Clin Cancer Res. 2020. PMID: 32102950 Free PMC article.
-
Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.Clin Cancer Res. 2021 Mar 1;27(5):1580. doi: 10.1158/1078-0432.CCR-20-2698. Clin Cancer Res. 2021. PMID: 33649190 No abstract available.
References
-
- Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang W-T, Black TA, et al. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2020;26:2354–61.
-
- Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–35.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
